122 results about "Myogenic cell" patented technology

An analgesic benefit is realized by continuously supplying a peptide in vivo that activates an opioid receptor or that interferes with the binding of substance P to its receptors. The long-term, continuous provision of such a peptide can be accomplished by (a) transducing myogenic cells with DNA expressing the peptide and (b) administering the transduced myogenic cells to a patient, such that the cells continuously produce the peptide.

The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.

The present invention provides a system for treating heart disease using a combination of pro-angiogenesis therapy and cellular cardiomyoplasty. The system is particularly useful in treating patients with damaged myocardium due coronary artery disease, myocardial infarction, congestive heart failure, and ischemia. A pro-angiogenic factor (e.g., VEGF) or a means of delivering a pro-angiogenic factor (e.g., a genetically engineered adenovirus, adeno-asssociated virus, or cells) is administered to the heart in order to promote new blood vessel growth in an ischemic or damaged area of the patient's heart. Cells such as skeletal myoblasts or stem cells (e.g., mesenchymal stem cells) with the potential to divide, differentiate, and integrate themselves into the injured myocardium are then administered into the affected area of the heart. By inducing new blood vessels growth in the injured myocardium, the cells are better able to grow and become an integral part of the heart. The invention also provides kits for use in treating a patient using the inventive method. Such kits may contain cells, catheters, syringes, needles, cell culture materials, polynucleotides, media, buffers, etc.

The present invention provides a method for repairing damaged myocardium. The method comprises using a combination of cellular cardiomyoplasty and electrostimulation for myogenic predifferentiation of stem cells and to synchronize the contractions of the transplanted cells with the cardiac cells. The method comprises the steps of obtaining stem or myogenic cells from a donor, culturing and electrostimulating the isolated cells in vitro, and implanting the cells into the damaged myocardium.

An improved device and method for extended repair and regeneration of muscle tissue. An exemplary device comprises (a) a scaffold comprising an ECM component; (b) a combination of growth factors such as VEGF and IGF; and (c) a population of myogenic cells. Implantation of the device leads to muscle regeneration and repair over an extended period of time.

Catheters and methods for their use are presented that provide automated delivery of cells to structures in the body such as degenerative or weak muscle. The catheters contain one or more sensing components and a system for delivery of cells such as autologous myogenic cells. The sensing component(s) triggers automatic discharge of the cells upon detection of a body surface that needs repair. The discharge of cells may occur through an automated lancing mechanism that alleviates operator error from manual injection timing. During use, an operator can position the catheter end to a structure in need of cellular repair, and the device can automatically discharge cells at a location and time as determined by conditions sensed at the catheter end. A catheter and system is particularly useful for repair of degenerative and or weak heart muscle, such as that found after a myocardial infarct. The catheters and methods of their use also may be used for cellular repair of other interior body structures, particularly muscles such as bladder, intestine, stomach and diaphram. The catheters provide greater use of myogenic cell therapy for heart disease, while avoiding complications of open heart surgery.

The present invention provides a method for repairing damaged myocardium. The method comprises using a combination of cellular cardiomyoplasty and electrostimulation for myogenic predifferentiation of stem cells and to synchronize the contractions of the transplanted cells with the cardiac cells. The method comprises the steps of obtaining stem or myogenic cells from a donor, culturing and electrostimulating the isolated cells in vitro, and implanting the cells into the damaged myocardium.

The invention relates to methods and materials for enhancing muscle mass or for the treatment of muscle disease in a subject, comprising introducing a cell which has a lower than normal level of myostatin signalling, into the subject.

The object of the present invention is to provide a method of preparing excellent cultured muscle cells having high metabolic capacity and insulin responsiveness, and further provide a method for the measurement of sensitive metabolic capacity using the cells. Moreover, its purpose is to provide a culture system / culture apparatus that can smoothly translocate such highly advanced cultured muscle cells intact to activity evaluation systems of a number of drugs. Moreover, the object of the present invention is to provide cultured muscle cells that are very suitable for measurement of the membrane-translocation activity of GLUT4 in an extraneous stimulus-dependent manner such as insulin, etc., and to provide a method for the measurement of the membrane-translocation activity of GLUT4 using the cells. The present invention is a method of preparing myotube cells, comprising a step (1) of culturing myoblast cells, a step (2) of differentiation-inducing the myotube cells into the myoblast cells in a culture medium with a high content of amino acids, and a step (3) of applying an electric pulse to the differentiation-induced myotube cells, and a method for the measurement of insulin-dependent sugar uptake using the myotube cells prepared by said method, and relates to the method for the measurement, comprising applying insulin stimulation by culturing the cells in a culture medium containing insulin, culturing the cells in the culture medium further supplemented with sugar, and measuring the sugar uptake. Furthermore, the present invention relates to a differentiation-type culture myotube cell constitutively expressing a recombinant GLUT4 having a labeled substance at its extra-cellular site, which is prepared by co-culturing wild-type myoblast cells and recombinant myoblast cells constitutively expressing said recombinant GLUT4, and a method for the measurement of membrane-translocation activity of the recombinant GLUT4 using the cells, and particularly a method for the measurement of insulin-dependent sugar uptake activity.

The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.

The present invention provides a method for enhancing regeneration of the myocardium. The method comprises the steps of applying electrical stimulation to an injury site in the myocardium. The method can be used in combination with implantation of myogenic cells into the injury site. The electrical stimulation may be applied before or after the implantation.

Since the multipotent progenitor / stem cells isolated and cultured from the cord blood-derived mononuclear cells according to the method of the present invention are capable of differentiating into several types of cells including neurons, osteoblasts, myoblasts, endothelial cells, hepatocytes and dendritic cells, they can be effectively used for a cell therapy, a cell restoration technique or an organ production.

Disclosed are products and methods to promote myoblast activation and cardiac and skeletal muscle growth or regeneration, and to treat heart and skeletal muscle diseases, based on the identification of cellular processes affected by prelamin A processing.

The invention discloses a CHO cellar strain of high-effective expressive exogenous rhBMP2, which is characterized by the following: adopting CHO-dhfr- in the dihydrofolic acid reductase flaw-typed Chinese hamster ovary cell as host cell; infecting exogenous hBMP2 plasmid; adopting secretory expressive product to induce myoblast system C2C12 to display the activity to stimulate sclerotomal cell; obtaining single-clone strain of CHO (rhBMP-2) with the content of BMP2 at 7.83ug / 24h*106; fitting for clinic treatment.

The present invention provides a method for producing a mesenchymal stem cell having an ability to differentiate into a myoblast by culturing a pluripotent stem cell derived from a human or animal, including: i) preparing the pluripotent stem cell that has been cryopreserved, ii) sub-culturing the prepared pluripotent stem cell in an undifferentiated state for a prescribed number of times, iii) culturing the subcultured pluripotent stem cell under conditions that enable induction of differentiation into an adipocyte in vitro, and iv) separating and collecting a CD105-positive cell during the culturing process.

Compositions and methods of treating mammalian diseases using myoblasts, and / or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and / or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and / or fatal. Treatment of these conditions is not limited to the usage of mechanical, electrical or physical properties of these myogenic cells, but includes the usage of biochemicals secreted / released by the latter. The present invention discloses the use of normal myoblasts to deliver the complete normal genome to effect genetic repair, or to augment the size, or the function of tissues or organs. Certain conditions may be better served with genetically altered myogenic cells derived from gene transduction, whereas others may be better served with cytoclimes converter cells. Endogenous biochemical(s) are used to control cell fusion of myoblasts among themselves or with other cell types. An automated cell processor within a cell bank which enables the manufacture, at a single run, of unprecedented large quantities (greater than 100 billion) of normal or genotypically or phenotypically altered myogenic cells is also disclosed.

The invention discloses a production mold for porous reticular cultured meat with regularly arranged micro-columns and a production method of porous muscle tissue based on the mold. Myogenic cells, type I collagen, a DMEM medium containing phenolic red and a sodium hydroxide solution are mixed, a mixture containing cells is prepared, the mixture containing the cells is added into the mold, and hydrogel muscle tissue is cultured at 37 DEG C after 2 hours in an incubator containing 5% carbon dioxide. A growth medium is added, after the hydrogel muscle tissue is cultured for 1-3 d, the growth medium is changed into a differential medium, after the hydrogel muscle tissue is cultured in the differential medium for 5-7 d, the porous reticular muscle tissue is prepared, so that the hydrogel muscle tissue can contract between the micro-columns to form muscle bundles, contracting space around the micro-columns due to the muscle bundles can increase the diffusion of nutrients to the cells, wastedischarge is facilitated, spatial pattern of mechanical tension is controlled to guide the partial three-dimensional cell arrangement, differentiation is promoted, and the production of larger in vitro, in line with industrial production of cultured meat is realized.

The invention provides means and methods for transduction of a skeletal muscle cell and / or a muscle cell specific precursor thereof. Provided is the use of a gene delivery vehicle derived from an adenovirus, having a tropism for said cells, for the preparation of a medicament. In a preferred aspect of the invention, said gene delivery vehicle comprises at least a tropism determining part of an adenoviral fiber protein of subgroup B and / or F. More preferably, said gene delivery vehicle comprises at least part of a fiber protein of an adenovirus of stereotype (11, 16, 35, 40 and / or 51) or a functional part, derivative and / or analogue thereof.

The invention is directed to a method for producing an edible composition, comprising incubating a three-dimensional porous scaffold and a plurality of cell types comprising: myoblasts or progenitor cells thereof, at least one type of extracellular (ECM)-secreting cell and endothelial cells or progenitor cells thereof, and inducing myoblasts differentiation into myotubes.

The invention provides a drug for promoting myoblast proliferation and improving myoblast autophagy level, which is characterized in that the active ingredient of the drug is DNA tetrahedron. The invention also provides a new drug for promoting muscle regeneration, which is prepared by taking a DNA tetrahedron as an active ingredient and adding pharmaceutically acceptable auxiliary materials. Theinvention provides the new application of the DNA tetrahedron in preparation of muscle regeneration promoting drugs, and the DNA tetrahedron has a very good application prospect.

The invention is directed to a method for producing an edible composition, comprising incubating a three-dimensional porous scaffold and a plurality of cell types comprising: myoblasts or progenitor cells thereof, at least one type of extracellular (ECM)-secreting cell and endothelial cells or progenitor cells thereof, and inducing myoblasts differentiation into myotubes.

The invention provides a secure expression vector for specific over-expression of pig endogenous gene IGF1 (C1 : Ea) in pig skeletal muscle. The vector comprises an expression cassette composed of the pig endogenous sequence sk-alpha-actinPromoter / IGF1 (C1 : Ea) / sk-alpha-actin3'UTR / SV40 enhancer in series. The expression vector verifies on a cell scale that the skeletal muscle specific sk-alpha-actin promoter can be expressed efficiently in myoblasts, and expressed at lower level in PET cells having myogenic differentiation potential, but not expressed in other type cells. By using the constructed vector for preparing transgenic mice, the detected mRNA expression level and protein expression level of the IGF1 gene in the skeletal muscle of the transgenic mice via quantification PCR and WesterBlot are 15 times and 3.5 times that of the wild mice respectively; and the IGF1 gene can be only expressed in the skeletal muscle efficiently.

The invention discloses a method for preparing a bionic skeletal muscle composite tissue through multi-channel extrusion 3D biological printing. The preparation method comprises the following steps: preparing bone scaffold bionic bio-ink, periosteum bionic bio-ink, sarcolemma bionic bio-ink and muscle bionic bio-ink; respectively mixing MSCs and C2C12 with the corresponding bionic bio-inks; and printing and forming a bionic bone, bionic periosteum, bionic sarcolemma and bionic muscle four-layer composite tissue engineering scaffold by using a multi-channel extrusion 3D biological printer. Themethod for preparing the bionic skeletal muscle composite tissue through multi-channel extrusion 3D biological printing can minimize fibrosis during traumatic skeletal muscle injury recovery; the bionic skeletal muscle composite tissue prepared through multi-channel extrusion 3D biological printing can replace structures and functions of bones and skeletal muscles at the same time, and supports proliferation and differentiation of myoblasts and osteoblasts; and an implant is easy to customize by utilizing a 3D biological printing technology, so that the implant is suitable for any defect shape.

The purpose of the present invention is to provide a novel protein involved in adhesion and fusion between myoblasts in the course of the formation of byotube. The present invention relates to Meltrins, which a membrane protein having fusion, adhesion and aggregation activity of cells, especially myoblast; and to polypeptides of their domains, DNAs encoding them, antisense RNA for these DNAs, various antibodies to Meltrins and the polypeptides of their domains, expression vectors containing these DNAs, and transformants by these vectors; as well as to the process for producing Meltrins and the polypeptides of their domains using those transformants and medical compositions comprising Meltrins or antagonist against them as an effective ingredient.

A method for delivering a cell to a heart of a patient comprises the steps of providing an apparatus for intracardiac drug administration comprising a catheter wherein the catheter has at least one position sensor which generates signals responsive to the position of a catheter and a drug delivery device for delivering the cell. The catheter is inserted into a chamber of the heart at a site and the cell is delivered to the site with the drug delivery device in response to the signals from the position sensor. Typical cells useful for delivery are either myoblasts or myocytes. These cells may be utilized as either an expression vector for promoting angiogenesis or for cell transplantation and fusion through myogenesis.

The invention relates to oyster mushroom galactomannan as well as a preparation method and an application thereof, and belongs to the field of preparation of effective components of edible mushrooms.The pleurotus ostreatus galactomannan is obtained by performing normal-temperature wall-breaking extraction on dried fruiting bodies of pleurotus ostreatus, and combining extrusion separation, proteinremoval and ion exchange chromatography. According to the wall breaking in combination with extrusion filtration, in the preparation method, the extraction time is shortened, the reagent consumptionis reduced, the energy is saved, and the polysaccharide yield is improved; and an adopted extrusion filtration technology is suitable for separation of a viscous solution, and the obtained oyster mushroom galactomannan has the functional activity of protecting myocyte oxidative damage, and can be used for preparing auxiliary medicines and health foods for protecting myocyte oxidative damage.

The invention relates to a device for standardizing myoblast differentiation into myotubes, comprising a substrate (1) and at least one cell-adhesive pattern (2) for culturing myoblasts on said substrate, wherein:said pattern (2) has an elongated surface comprising a central region (2C) and two lateral regions (2L) extending from said central region in both directions along a longitudinal axis of the pattern with a contour discontinuity between the central region (2C) and each lateral region (2L),the ratio between the maximum width (WC) of the central region (2C) and the maximum width (WL) of the lateral regions (2L) is greater than or equal to 2,the ratio between the length (L) and the maximum width (WC) of the pattern (2) is less than or equal to 4.The invention is also a method for standardizing myoblast differentiation into myotubes, comprising:(i) providing a device as described above,(ii) depositing myoblasts on at least one cell-adhesive pattern of said device,(iii) culturing said myoblasts in a differentiation medium during a determined incubation time so as to promote cell differentiation into myotubes and constrain elongation of the myotubes on the cell-adhesive pattern.Another aspect of the invention is a method for compounds screening in cell-based assays related to myotoxicity and drug discovery.

The present invention relates to establishing method of active cell strain for quantitative determination of bone morphogenetic protein (BMP). By means of the transgenic technology of molecular biology, partial promoter of BMP action target molecular osteocalcium together with leuciferinase report gene is transfered to myogenic cell C2C12, monoclonal cell strain to express leuciferinase report gene stably is obtained through screening and the reaction of the cell strains to BMP action is determined. Strain with high reaction strength to BMP stimulation and sensitive determination index is finally sorted. Specificity and stability test proves the stability and reliability of the cell strain and multiple BMP sample testing result shows that the action of BMP is correlated with leuciferinase activity linearly and directly. The cell strain of the present invention is suitable for quantitative determination of BMP activity.

The invention discloses a recombinant protein IGF (insulin-like growth factor) 1-24, which has an amino acid sequence shown in SEQ ID No.2, and is obtained by connecting a C-end of an IGF-1 sequence and an N-end of an MGF (mechano growth factor)-24 sequence through three GLY connectors. A research result shows that the recombinant protein can promote proliferation, differentiation, conglutination and migration of myoblast, can promote proliferation and migration of osteocyte, can promote damage repair of a nerve cell, can also promote proliferation of a myocardial cell, is obviously stronger than IGF-1 and MGF-24 in effect, can be prepared into a drug, can be used for treating related diseases of muscles, bones, nerves, myocardial damages and the like, and plays a positive and important promotion role in improvement of the survival quality of a sufferer.

Since the multipotent progenitor / stem cells isolated and cultured from the cord blood-derived mononuclear cells according to the method of the present invention are capable of differentiating into several types of cells including neurons, osteoblasts, myoblasts, endothelial cells, hepatocytes and dendritic cells, they can be effectively used for a cell therapy, a cell replacement therapy, an organ restoration technique or an organ production.